Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2014

View Archived Issues

Structure-based discovery of novel ITK inhibitors, GNE-9822 lead identified

A potent mGluR5 PAM shows promise in rodent cognition models

Results of a phase I dose-escalation study of a chikungunya virus vaccine

VX-787, first-in-class PB2 influenza polymerase inhibitor

arGEN-X reports preclinical data for ARGX-113

Glenmark Pharmaceuticals to begin IND-enabling studies of new bispecific antibody

Bristol-Myers Squibb and Celgene to evaluate immunotherapy/chemotherapy combination

Amicus Therapeutics reports phase III data for migalastat in Fabry disease

Pfizer and Crohn's & Colitis Foundation of America form IBD collaboration

Aeolus files IND for acute radiation syndrome candidate AEOL-10150

Illumina forms multiple collaborations for oncology genomics analysis

AM-9514, a GK activator with good pharmacokinetic profile in vivo

KalVista Pharmaceuticals confirms first-in-human trial of KVD-001

Potential AD treatment activates TGF-beta signaling pathway in the brain

Vertex Pharmaceuticals patents novel sodium channel blockers

Toyama designs novel antifungal agents

Researchers at Bayer Schering Pharma synthesize new products for cancer

Hanmi Pharm enters into agreement with Luye Pharma Group for poziotinib

Korean scientists present new anti-C5 MAbs

ViaCyte and Janssen enter rights agreement for type 1 diabetes cell therapy

Baxter's PEGylated rFVIII meets primary endpoint in phase III trial

Apixaban granted FDA approval for DVT and PE

EMA accepts Basilea Pharmaceutica's isavuconazole MAA for review

Lilly's ixekizumab superior to etanercept in phase III plaque psoriasis trials

Auxilium and BioSpecifics report positive data from phase IIa trial of Xiaflex

GSK to conduct phase II study of GSK-2862277 to prevent acute lung injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...